BridgeBio price target raised to $18 from $15 at BofA

BofA analyst Greg Harrison raised the firm’s price target on BridgeBio to $18 from $15 and keeps a Buy rating on the shares after the company announced "strong" PROPEL2 data from cohort 5 that the firm says "widely surpassed expectations as the highest mean AHV change from baseline ever published in achondroplasia." Following the update, BofA sees the achondroplasia program as BridgeBio’s lead asset and "potentially best in class for achondroplasia," the analyst tells investors.